Important safety information
Warning: risk of thyroid C-cell tumors. In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is not known whether they cause such tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use if you are pregnant or planning pregnancy, or have had a serious allergic reaction to semaglutide or tirzepatide. Tell your physician if you have a history of pancreatitis, gallbladder or kidney problems, diabetic retinopathy, severe stomach problems, or depression or suicidal thoughts, and about every medication you take, especially insulin or sulfonylureas.
Serious side effects may include pancreatitis, gallbladder problems, low blood sugar, kidney problems from dehydration, serious allergic reactions, vision changes and increased heart rate. The most common side effects are nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, fatigue and injection-site reactions.
This summary is based on the prescribing information for FDA-approved semaglutide and tirzepatide and is not complete. [HAVE BIONOMY'S MEDICAL AND LEGAL TEAM REVIEW THIS BLOCK BEFORE PUBLISHING.] Compounded medications are not FDA-approved as finished products; they are prepared by state-licensed pharmacies for individual patients based on a prescription from a licensed practitioner.